ArticleObesity (Silver Spring, Md.)2020
The Mitigating Effect of Phentermine and Topiramate on Weight Regain After Roux-en-Y Gastric Bypass Surgery.
Article in Obesity (Silver Spring, Md.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Therapeutic Options for Recurrence of Weight and Obesity Related Complications After Metabolic and Bariatric Surgery: An IFSO Position Statement.Obesity surgery · 2024Guideline
- Obesity in South and Southeast Asia-A new consensus on care and management.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2023Guideline
- Combination Pharmacotherapies for Obesity-Current Evidence and Future Directions.Endocrinology, diabetes & metabolism · 2026Review
- Pharmacotherapy and metabolic/bariatric surgery: either or both?International journal of obesity (2005) · 2025Article
- Real world efficacy of naltrexone/bupropion for weight management in obesity and after bariatric surgery.International journal of obesity (2005) · 2025Article
- The Interplay Between Psychological and Neurobiological Predictors of Weight Regain: A Narrative Review.Nutrients · 2025Review
- Novel perspectives on the link between obesity and cancer risk: from mechanisms to clinical implications.Frontiers of medicine · 2024Review
- Review
- Adjuvant and Neo-Adjuvant Anti-Obesity Medications and Bariatric Surgery: A Scoping Review.Current obesity reports · 2024Article
- Update on Pediatric Anti-obesity Medications-Current Landscape and Approach to Prescribing.Current obesity reports · 2024Review
- Weight Regain after Metabolic Surgery: Beyond the Surgical Failure.Journal of clinical medicine · 2024Review
- Prognosticating post-bariatric surgery outcomes and management of postoperative recurrent weight gain and diabetes recurrence.Frontiers in nutrition · 2024Review
- How to address weight regain after bariatric surgery in an individualized way.Reviews in endocrine & metabolic disorders · 2023Review
- Metabolic and bariatric surgery and obesity pharmacotherapy for cancer prevention: current status and future possibilities.Journal of the National Cancer Institute. Monographs · 2023Review
- Effectiveness of semaglutide versus liraglutide for treating post-metabolic and bariatric surgery weight recurrence.Obesity (Silver Spring, Md.) · 2023Article
- An Updated Approach to Antiobesity Pharmacotherapy: Moving Beyond the 5% Weight Loss Goal.Journal of the Endocrine Society · 2023Article
- Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022.Obesity pillars · 2022Article
- Pharmacologic management of weight regain following bariatric surgery.Frontiers in endocrinology · 2022Article
- Endoscopic Evaluation and Management of Late Complications After Bariatric Surgery: a Narrative Review.Obesity surgery · 2021Review
- Phentermine-Induced Acute Kidney Injury Secondary to Uncontrolled Hypertension in a Patient with Weight Regain Post-bariatric Surgery.Obesity surgery · 2021Article
Corrections and comments
- Commented on by
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
objectiveWeight regain (WR) after Roux-en-Y gastric bypass surgery (RYGB) starts to occur 2 years after surgery, ultimately affecting at least 25% of patients. A limited number of studies have evaluated the impact of antiobesity medications (AOMs) on this phenomenon.
methodsThis study reviewed the electronic medical records of 1,196 patients who underwent RYGB between 2004 and 2015. WR was evaluated by comparing each patient's weight during subsequent postoperative office visits to nadir weight (lowest weight after RYGB, n = 760), taking into consideration the interval during which WR occurred. Patients who were prescribed AOMs and came to follow-up visits were classified as adherent users, whereas those who missed their follow-up visits were considered nonadherent. This study used a linear mixed model, Cox regression, and generalized equation estimator to determine the impact of AOMs on WR trajectory, hazard ratio for time to event, and odds ratio for repeated event occurrence, respectively.
resultsDespite the lack of a unified protocol for using AOMs, the three statistical models converged to show that phentermine and topiramate, used individually or in combination, can significantly reduce WR after RYGB.
conclusionsPhentermine and topiramate are effective in mitigating WR after RYGB. Further studies are needed to help ascertain optimal use of AOMs after bariatric surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.